DeepMed Research

Zhejiang Cancer Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Employees: -

Market Cap: -

Website: http://www.zchospital.com

Clinical Trials

Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC

Phase 2

Recruiting

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Radiation: Neoadjuvant Radiotherapy
Drug: Neoadjuvant Chemotherapy
Drug: Immunotherapy

First Posted Date: 2022-08-19

Last Posted Date: 2022-08-19

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 100

Registration Number: NCT05507411

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hanzhou, Zhejiang, China
🇨🇳
The First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU), Hanzhou, Zhejiang, China
🇨🇳
Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang, China

Effect of Propofol and Desflurane on Nucleic Acid of Liver Circulating Tumor

Phase 2

Completed

Conditions: Hepatocellular Carcinoma
Propofol Adverse Reaction
Desflurane Adverse Reaction
Circulating Tumor Cells

Interventions: Drug: Desﬂurane
Drug: Propofol

First Posted Date: 2022-08-16

Last Posted Date: 2022-08-16

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 60

Registration Number: NCT05502458

Locations: 🇨🇳
Zhejiang Cancer hospital, Hangzhou, Zhejiang, China

A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor Exposure

Phase 2

Active, not recruiting

Conditions: Epithelial Ovarian Cancer

Interventions: Drug: Pamiparib

First Posted Date: 2022-08-05

Last Posted Date: 2024-01-26

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 15

Registration Number: NCT05489926

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Effect of Zoledronic Acid Treatment on Bone-related Events in Breast Cancer Patients With Bone Metastases: a Prospective, Multicenter, Real-world Study

Not yet recruiting

Conditions: Histologically Confirmed Breast Cancer ,Diagnosis of Bone Metastasis

Interventions: Other: Non-intervention

First Posted Date: 2022-07-29

Last Posted Date: 2022-07-29

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 1000

Registration Number: NCT05480189

Clinical Application Value of Remazolam Combined With Sugammadex Sodium in Anesthesia for Endotracheal Surgery Under Bronchoscopy

Phase 4

Completed

Conditions: Endobronchial Metastases
Bronchoesophageal Fistula
General Anesthetic Drug Adverse Reaction

Interventions: Drug: Remimazolam
Drug: Propofol
Drug: Rocuronium
Drug: Remifentanil
Drug: oxycodone
Drug: Sugammadex Sodium
Drug: Flumazenil

First Posted Date: 2022-07-21

Last Posted Date: 2022-10-26

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 34

Registration Number: NCT05468671

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hanzhou, China

Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination Deficiency

Phase 2

Not yet recruiting

Conditions: Triple Negative Breast Cancer
Homologous Recombination Deficiency

Interventions: Drug: Niraparib

First Posted Date: 2022-07-18

Last Posted Date: 2022-07-18

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 50

Registration Number: NCT05461690

Transversus Thoracic Muscle Plane Combined With Pectoral Nerves Block for Breast Cancer Surgery

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Procedure: the combination of transversus thoracic muscle plane and pectoral nerves blocks
Procedure: the pectoral nerves block only

First Posted Date: 2022-07-07

Last Posted Date: 2023-11-21

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 116

Registration Number: NCT05448638

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

The Role of Clean Intermittent Catheterization in Patients Undergoing Radiotherapy After Radical Hysterectomy for Cervical Cancer

Not Applicable

Completed

Conditions: Uterine Cervical Neoplasms

Interventions: Device: Indwelling catheterization
Device: Clean Intermittent Catheterization

First Posted Date: 2022-06-08

Last Posted Date: 2022-06-08

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 80

Registration Number: NCT05410444

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China,, China

SBRT for Oligoprogressive NSCLC After First Line Treatment With Immune Checkpoint Inhibitors

Phase 2

Conditions: NSCLC Stage IV

Interventions: Radiation: SBRT

First Posted Date: 2022-05-24

Last Posted Date: 2022-05-24

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 28

Registration Number: NCT05387044

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

A Retrospective Study of Immunotherapy in Conversion Therapy of Unresectable Gastric Cancer

Recruiting

Conditions: Unresectable Gastric Cancer

First Posted Date: 2022-05-23

Last Posted Date: 2022-11-09

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 100

Registration Number: NCT05385809

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy